文献速递介入腹部MRCT

肝细胞癌经动脉放射性栓塞治疗的血管区放射病理学分析

Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

研究12例肝细胞癌患者接受钇-90经动脉放射性栓塞(TARE)后,比较消融剂量(≥190 Gy)与非消融剂量(<190 Gy)的放射病理学相关性。消融剂量组5/6、非消融剂量组2/6获得完全病理坏死。T2高信号、肝细胞特异性对比剂无摄取及血管区平台或持续强化与完全病理坏死相关,预测效能与EASL和mRECIST标准相似。

要点

  • TARE术后血管区肝细胞特异性对比剂无摄取、T2高信号、平台或持续强化可能提示完全病理坏死。
  • 消融剂量(≥190 Gy)组完全病理坏死5/6,非消融剂量(<190 Gy)组2/6。
  • 上述影像征象预测完全病理坏死的效能与EASL和mRECIST标准相似。

核心结论

  • 血管区肝细胞特异性对比剂无摄取、T2加权序列信号增高及平台或持续强化可能是TARE治疗肝细胞癌后完全病理坏死的MRI替代标志物,这些表现与EASL和mRECIST疗效标准相关;需进一步研究确定其作为常规影像标准辅助手段的作用。

研究设计与样本

  • 研究纳入12例肝细胞癌患者,接受消融剂量(≥190 Gy)和/或非消融剂量(<190 Gy)TARE,采用段、叶或联合方式作为手术新辅助或移植桥接治疗;TARE前后使用肝细胞特异性对比增强MRI或增强CT分析靶肿瘤及治疗血管区;疗效采用EASL和mRECIST标准分级;组织学发现(包括肿瘤坏死百分比及邻近肝实质效应)与影像特征进行相关性分析。

关键影像表现/征象

  • 血管区T2加权成像高信号与完全病理坏死相关。
  • 血管区肝细胞特异性钆对比剂无摄取与完全病理坏死相关。
  • 血管区平台或持续强化动力学与完全病理坏死相关。

诊断标准与关键数值

  • 消融剂量(≥190 Gy)组完全病理坏死5/6,非消融剂量(<190 Gy)组完全病理坏死2/6。
  • T2高信号、肝细胞特异性对比剂无摄取及平台或持续强化预测完全病理坏死的效能与EASL和mRECIST标准相似。

临床应用与阅片要点

  • 作者认为血管区肝细胞特异性对比剂无摄取、T2信号增高及平台或持续强化可能是TARE后完全病理坏死的MRI替代标志物。
  • 作者指出这些表现与EASL和mRECIST疗效标准相关,需进一步研究确定其作为常规影像标准辅助手段的作用。

局限性

  • 原文指出需进一步研究以确定这些表现作为常规影像标准辅助手段的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response.

METHODS: Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (< 190 Gy) TARE delivered in a segmental, lobar, or combined fashion as a surgical neoadjuvant or bridge to transplantation. Both targeted tumor and treatment angiosome were analyzed before and after TARE utilizing hepatocyte-specific contrast-enhanced MRI or contrast-enhanced CT. Responses were graded using EASL and mRECIST criteria. Histologic findings including percent tumor necrosis and adjacent hepatic substrate effects were correlated with imaging features.

RESULTS: Complete pathologic necrosis (CPN) was observed in 7/12 tumors post-TARE. Ablative and non-ablative dosing resulted in CPN in 5/6 and 2/6 tumors, respectively. Hyperintensity on T2-weighted imaging, the absence of hepatocyte-specific gadolinium contrast uptake, and plateau or persistent enhancement kinetics in the angiosome correlated with CPN and performed similarly to EASL and mRECIST criteria in predicting CPN.

CONCLUSIONS: The absence of hepatocyte-specific contrast uptake, increased signal on T2-weighted sequences, and plateau or persistent enhancement in the angiosome may represent MRI surrogates of CPN following TARE of HCC. These findings correlated with EASL and mRECIST response criteria. Further investigation is needed to determine the role of these findings as possible adjuncts to conventional imaging criteria.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ahmed AF, Samreen N, Grajo JR, et al. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma. Abdom Radiol (NY). 2018. PMID: 29052747. doi:10.1007/s00261-017-1354-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。